Insights

Targeted Biotech Partners Glyphic's single-molecule protein sequencing platform enables detailed analysis of proteins within complex mixtures, unlocking new possibilities for drug target validation, proteomics-driven biomarker discovery, and mechanistic biology. Ideal customers include biopharma R&D teams, proteomics-focused biotech startups, and CROs seeking deeper protein-level insights beyond genomic data. Action: pursue targeted outreach to proteomics-focused pharma groups, academic collaborators, and CROs; offer pilot collaborations or licensing to validate workflows and demonstrate value in proteomics pipelines.

Analytics as Service Built on a stack that includes Metabase and Microsoft Azure, Glyphic can host proteomics data and deliver actionable analytics and dashboards. This creates an opportunity to sell end-to-end data platforms that pair sequencing outputs with reproducible BI and visualization for fast hypothesis testing. Action: position as an integrated data platform with hosting, analytics, and support, offer pilot dashboards tailored to target discovery projects, and explore bundled pricing with cloud partners.

Global Collaboration Potential Recent investor activity in Europe, including LongeVC, signals international validation and potential for cross-border collaborations. This opens opportunities to partner with European pharma, biotech firms, and academic consortia on joint development programs and grant-funded projects. Action: map EU biotech partners and grant opportunities, pursue co-development deals, and consider establishing a regional presence or partner network to accelerate deals in EMEA.

Licensing Potential Glyphic's first-of-its-kind sequencing capability presents licensing and OEM collaboration opportunities with larger biotech vendors and CROs seeking to integrate proteomics into their pipelines. Action: develop licensing terms for platform access and data rights, run pilots with potential partners to validate integration, and explore co-development arrangements to accelerate market adoption.

Growth Ecosystem Partnerships With a growing team and active investor interest, building a partner ecosystem can accelerate market penetration. Action: establish a reseller and technology-partner program with training, certification, and joint go-to-market plans; target instrumentation vendors, academic labs, and service providers to broaden reach and adoption of the platform.

Glyphic Biotechnologies Tech Stack

Glyphic Biotechnologies uses 8 technology products and services including Metabase, oEmbed, Claude by Anthropic, and more. Explore Glyphic Biotechnologies's tech stack below.

  • Metabase
    Business Intelligence
  • oEmbed
    Dev Tools
  • Claude by Anthropic
    Generative Ai
  • Lenis
    Javascript Libraries
  • Framer Motion
    Javascript Libraries
  • Microsoft Azure
    Platform As A Service
  • Greenhouse
    Recruitment Marketing
  • Google Search Console
    Web Analytics

Glyphic Biotechnologies's Email Address Formats

Glyphic Biotechnologies uses at least 2 format(s):
Glyphic Biotechnologies Email FormatsExamplePercentage
First@glyphic.bioJohn@glyphic.bio
96%
FirstL@glyphic.bioJohnD@glyphic.bio
4%

Frequently Asked Questions

What is Glyphic Biotechnologies's official website and social media links?

Minus sign iconPlus sign icon
Glyphic Biotechnologies's official website is www.glyphic.bio and has social profiles on LinkedInCrunchbase.

What is Glyphic Biotechnologies's SIC code NAICS code?

Minus sign iconPlus sign icon
Glyphic Biotechnologies's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Glyphic Biotechnologies have currently?

Minus sign iconPlus sign icon
As of July 2026, Glyphic Biotechnologies has approximately 34 employees across 2 continents, including North AmericaEurope. Key team members include Vice President, Operations: S. V.Director Of Intellectual Property: E. J. S.Staff Scientist: A. Y.. Explore Glyphic Biotechnologies's employee directory with LeadIQ.

What industry does Glyphic Biotechnologies belong to?

Minus sign iconPlus sign icon
Glyphic Biotechnologies operates in the Biotechnology Research industry.

What technology does Glyphic Biotechnologies use?

Minus sign iconPlus sign icon
Glyphic Biotechnologies's tech stack includes MetabaseoEmbedClaude by AnthropicLenisFramer MotionMicrosoft AzureGreenhouseGoogle Search Console.

What is Glyphic Biotechnologies's email format?

Minus sign iconPlus sign icon
Glyphic Biotechnologies's email format typically follows the pattern of First@glyphic.bio. Find more Glyphic Biotechnologies email formats with LeadIQ.

How much funding has Glyphic Biotechnologies raised to date?

Minus sign iconPlus sign icon
As of July 2026, Glyphic Biotechnologies has raised $79M in funding. The last funding round occurred on Sep 26, 2025 for $38M.

When was Glyphic Biotechnologies founded?

Minus sign iconPlus sign icon
Glyphic Biotechnologies was founded in 2021.
Glyphic Biotechnologies logo

Glyphic Biotechnologies

Biotechnology ResearchCalifornia, United States11-50 Employees

Glyphic Biotechnologies is a biotechnology startup focused on proteomics, headquartered in Berkeley, California. The company aims to sequence proteins to reveal how biological systems function, offering a next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease. It has a small to mid-sized team and was founded in New York in 2021 by Daniel Estandian and Joshua Yang. Recent coverage in December 2024 notes the company is developing a protein sequencing platform capable of analyzing the sequence of each protein in a complex mixture.

Its target customers are researchers in biology and disease-related proteomics, including academic and industrial researchers who study proteins and their roles. The company operates within the biotechnology research industry, seeking to position itself as a provider of advanced proteomics capabilities that extend beyond DNA-derived insights.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2021
Employees
11-50

Section iconFunding & Financials

  • $79M

    Glyphic Biotechnologies has raised a total of $79M of funding over 14 rounds. Their latest funding round was raised on Sep 26, 2025 in the amount of $38Mas a series_a.

  • $10M$25M

    Glyphic Biotechnologies's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $79M

    Glyphic Biotechnologies has raised a total of $79M of funding over 14 rounds. Their latest funding round was raised on Sep 26, 2025 in the amount of $38Mas a series_a.

  • $10M$25M

    Glyphic Biotechnologies's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.